Drug Trial Radar · NCT00172081
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,532
Actual
Start
Apr 27, 2000
Primary completion
Nov 7, 2003
Study completion Nov 7, 2003
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84) (rhPTH \[1-84\]), on fracture incidence in women with postmenopausal osteoporosis, the TOP study.
Conditions
- Osteoporosis
Interventions
placeboDrug
Daily subcutaneous injection with placebo
ALX1-11Drug
PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare effects of 18 months of treatment with ALX1-11/placebo on the incidence of new and/or worsened thoracic and lumbar vertebral fractures in postmenopausal women with osteoporosis receiving calcium and vitamin D3 supplementsTime frame: At Month 18
Locations
174 sites in 9 countries. Site status is shown where the registry gives one.
Capstone Clinical Trials
Birmingham, Alabama
'The University of Alabama at Birmingham
Birmingham, Alabama
'Rheumatology Associates of North Alabama
Huntsville, Alabama
'Radiant Research - Phoenix
Phoenix, Arizona
'Robin K. Dore, M.D., Inc.
Anaheim, California
'Osteoporosis Medical Center
Beverly Hills, California
'East Bay Clinical Trial Center
Concord, California
'Loma Linda Osteoporosis Research Center
Loma Linda, California
'The Foundation for Osteoporosis Research and Education
Oakland, California
'Desert Medical Advances
Palm Desert, California
'VA Palo Alto Health Care System
Palo Alto, California
'Boling Clinical Trials
Rancho Cucamonga, California
'Radiant Research - San Diego
San Diego, California
'S.D. Arthritis & Osteoporosis Medical Clinic
San Diego, California
'San Francisco General Hospital
San Francisco, California
'Community Research Centers
Santa Ana, California
'Denver Arthritis Clinic
Denver, Colorado
'Colorado Center for Bone Research
Lakewood, Colorado
'Longmont Medical Research Network
Longmont, Colorado
'Northeast Clinical Research, LLC
Hamden, Connecticut
'Georgetown University Medical Center
Washington D.C., District of Columbia
'RASF - Clinical Research Center
Boca Raton, Florida
'ICSL Clinical Studies
Fort Myers, Florida
'The Center for Diabetes and Endocrine Care
Hollywood, Florida
'Florida Wellcare Alliance
Inverness, Florida
'Radiant Research - Lake Worth
Lake Worth, Florida
'Osteoporosis Center University of Miami
Miami, Florida
'Renstar Medical Group
Ocala, Florida
'Diabetes and Endocrinology Treatment Center
Palm Beach Gardens, Florida
'The Arthritis Center
Palm Harbor, Florida
'The Centre for Arthritis and Rheumatic Diseases
South Miami, Florida
'ICSL Clinical Studies
St. Petersburg, Florida
'Radiant Research - Stuart & LakeWorth
Stuart, Florida
'Palm Beach Research Center
West Palm Beach, Florida
'The Emory Clinic
Atlanta, Georgia
'Radiant Research
Honolulu, Hawaii
'Intermountain Orthopaedics
Boise, Idaho
'ICSL-Clinical Studies
Bloomington, Illinois
Rush-Prebyterian-St.Luke's Medical Center
Chicago, Illinois
'The University of Chicago
Chicago, Illinois
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.